QualityStocks'  Instablog

POZEN Inc. is a pharmaceutical company committed to transforming medicines that transform lives. By utilizing a unique in-source model and a focus on integrated therapies, it has successfully developed and obtained FDA approval of two self-invented products in two years. This is something that almost no other small pharmaceutical company has done.

The company today announced the appointment of Mark N. Matthews as vice-president of marketing and sales. Mr. Matthews will be responsible for driving the commercial strategy of all pipeline products. Prior to joining POZEN, Mr. Matthews held several key commercial positions, including vice-president of marketing and sales for Javelin Pharmaceuticals and vice-president of neurology marketing for Biogen Idec.

Mobile and digital communications are changing the way healthcare professionals and patients receive health information. POZEN plans to take advantage of these trends as a core driver of its business model. Mr. Matthews shares POZEN’s philosophy regarding the way new medicines are marketed and is well versed in the use of digital media.

Mr. Matthews’ efforts will begin with POZEN’s lead product candidate, PA32540, a coordinated-delivery tablet of enteric-coated aspirin and immediate-release omeprazole. This novel, patented oral product is currently in Phase 3 clinical development in the US, with New Drug Application (NDA) submission scheduled for 2012. This product is the first in a portfolio of aspirin therapies that POZEN is developing which are designed to enable the full power of aspirin by reducing its negative effects on some patients’ gastrointestinal tract.

For further information on POZEN Pharmaceuticals, please visit the company’s website at pozen.com

Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net